TICKERNERD
Menu
ALKSALKSHealthcare · Drug Manufacturers - Specialty & Generic

ALKS Stock Forecast: Alkermes Plc Price Predictions for 2026-2027

Last close, 14 Aug 2026
$49
−0.79% on the day

The 18 Wall Street analysts covering Alkermes Plc hold a median 12-month price target of $58 — +18.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$8.2B
Ticker Nerd rank
60 / 100
Median analyst target
$58
Analysts covering
18
Total return, dividends reinvested
1W
−0.2%
1M
−4.9%
YTD
+75.3%
1Y
+73.6%
From 52W high
−11.2%
From 52W low
+85.0%
$27
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALKS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alkermes Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Value
97
Quality
83
Momentum
81
Revisions
49
Growth
39
Accruals
38
Issuance
22
Size
18

Volatility (98): The share price has been relatively steady.

Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALKS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALKS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26ALKSHigh $72Median $58Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says18 analysts
14 Buy3 Hold1 Sell
Low $38Median $58High $72

The green dot is the last close — the median target sits +18.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 July 2026BairdMaintainsOutperform$48 → $58
29 July 2026JP MorganMaintainsNeutral$60 → $61
28 July 2026Piper SandlerReiteratesOverweight$43 → $65
20 July 2026StifelReiteratesBuy$45 → $63
20 July 2026StifelReiteratesBuy—
13 July 2026JP MorganReinstatesNeutral$60
13 July 2026NeedhamMaintainsBuy$61 → $62
13 July 2026NeedhamMaintainsBuy—
2 July 2026MizuhoMaintainsOutperform—
29 June 2026B of A SecuritiesDowngradeUnderperform—
29 June 2026Wells FargoMaintainsOverweight—
24 June 2026NeedhamMaintainsBuy—
22 June 2026TD CowenMaintainsBuy—
18 June 2026NeedhamMaintainsBuy—
9 June 2026RBC CapitalMaintainsOutperform—
13 May 2026BairdMaintainsOutperform—
6 May 2026NeedhamMaintainsBuy—
6 May 2026UBSMaintainsBuy—
6 May 2026Wells FargoMaintainsOverweight—
9 Apr 2026B of A SecuritiesMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALKS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ALKS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2024.7%
Analysts raising
0
Analysts cutting
0
Fundamentals

Alkermes Plc (ALKS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
129.1×

Cheaper than 6% of US stocks

Price / sales
4.9×

Cheaper than 26% of US stocks

Price / book
4.5×

Cheaper than 24% of US stocks

EV / EBITDA
32.1×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
27.0%

Higher than 77% of US stocks

Earnings growth (YoY)
−99.4%

Higher than 2% of US stocks

Gross margin
84.3%

Higher than 93% of US stocks

Operating margin
15.5%

Higher than 73% of US stocks

Net margin
4.0%

Higher than 57% of US stocks

Returns & dividend
Return on equity
3.9%

Higher than 51% of US stocks

Return on assets
4.2%

Higher than 72% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALKS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ALKSAlkermes Plc$8.2B
60
HIMSHims & Hers Health, Inc.$6.6B
17
LNTHLantheus Holdings, Inc.$6.5B
88
LQDALiquidia Corp.$6.4B
78
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
AMRXAmneal Pharmaceuticals, Inc.$5.7B
79
ELANElanco Animal Health, Inc.$11.8B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alkermes Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALKS news & analysis

ALKS Stock Rises 27% in 3 Months: Here's What You Should Know

Zacks Investment Research · 12 Aug 2026positive

Alkermes (ALKS) shares have risen approximately 27% over the past three months, gaining 26.5% during that period. The advance is attributed to strong proprietary product sales and progress in its pipeline as the company looks toward the rest of 2026.

Why it matters — For ALKS watchers, the article highlights that momentum from proprietary product sales and pipeline advancement is underpinning the stock's recent gains.

Alkermes plc (ALKS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 28 July 2026neutral

Alkermes plc published the transcript of its Q2 2026 earnings call, covering the company's quarterly financial discussion with analysts.

Why it matters — ALKS watchers monitor earnings call transcripts for management's commentary on financial performance, strategy, and outlook.

Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down

Zacks Investment Research · 28 July 2026neutral

Alkermes reported break-even Q2 earnings while exceeding revenue estimates, driven by surging product sales and momentum from Lumryz. The company maintained its 2026 revenue outlook, though the stock declined following the results.

Why it matters — The report shows Alkermes beating revenue expectations with strong product sales growth while reaffirming its long-term guidance, making it a key check on the company's commercial execution.

Compared to Estimates, Alkermes (ALKS) Q2 Earnings: A Look at Key Metrics

Zacks Investment Research · 28 July 2026neutral

Zacks Investment Research reported that Alkermes (ALKS) released its Q2 2026 earnings, with revenue and EPS results available. The report compares key metrics against Wall Street estimates and year-ago figures.

Why it matters — This earnings analysis helps ALKS watchers understand how the company's core business metrics performed relative to market expectations and prior periods.

Alkermes Q2 Earnings Call Highlights

MarketBeat · 28 July 2026positive

Alkermes reported second-quarter 2026 revenue of $496 million, driven by growth in its proprietary product portfolio and the first full-quarter contribution of LUMRYZ following its acquisition of Avadel. The company also noted progress in its orexin development pipeline and reiterated most of its full-year financial outlook.

Why it matters — ALKS watchers would note the revenue growth from proprietary products and the initial LUMRYZ contribution, which signal how the Avadel acquisition and pipeline progress are shaping the company's near-term performance.

FAQ

Frequently asked questions about ALKS stock

What is the ALKS stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Alkermes Plc have a median 12-month price target of $58, with estimates ranging from $38 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALKS stock a buy right now?

Of the 18 analysts covering Alkermes Plc, 14 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alkermes Plc 60 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALKS?

As at 15 Aug 2026, Alkermes Plc ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will ALKS stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +18.2% from the last close, and Ticker Nerd's factor model ranks Alkermes Plc 60 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALKS stock forecast for 2030?

No analyst covering Alkermes Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALKS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $72 over the next 12 months.

How has ALKS stock performed over the past year?

Alkermes Plc returned +73.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alkermes Plc do?

Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia.

What is the latest news on ALKS?

The most recent item we track (Zacks Investment Research, 12 Aug 2026): "ALKS Stock Rises 27% in 3 Months: Here's What You Should Know". Alkermes (ALKS) shares have risen approximately 27% over the past three months, gaining 26.5% during that period. The advance is attributed to strong proprietary product sales and progress in its pipeline as the company looks toward the rest of 2026.

Company

About Alkermes Plc.

Alkermes plc is an Ireland-based, fully integrated global biopharmaceutical company focused on developing and commercializing innovative medicines in neuroscience. It specializes in treatments for serious mental illnesses, addiction, schizophrenia, bipolar I disorder, alcohol and opioid dependence, and sleep disorders such as narcolepsy and idiopathic hypersomnia. Key marketed products include Vivitrol for alcohol and opioid dependence, Aristada and Aristada Initio as long-acting injectables for schizophrenia, Lybalvi combining olanzapine and samidorphan for schizophrenia and bipolar I disorder, and manufacturing and royalty agreements for products like Invega long-acting formulations and Vumerity for multiple sclerosis. Alkermes employs proprietary technologies such as NanoCrystal, extended-release microsphere, and LinkeRx platforms to create competitively advantaged therapies. Its investigational pipeline features alixorexton, an oral orexin 2 receptor agonist advancing in phase 2 and 3 studies for narcolepsy types 1 and 2 and idiopathic hypersomnia, alongside other candidates like once-nightly sodium oxybate formulations. With R&D in Waltham, Massachusetts, and manufacturing in Wilmington, North Carolina, Alkermes plc plays a vital role in addressing unmet needs in psychiatric and neurological disorders through patient-inspired science and specialized commercial infrastructure. Founded in 1987 and headquartered in Dublin, Ireland, it serves healthcare and life sciences sectors worldwide.

CEO Mr. Blair C. Jackson · 2,050 employees · Ireland · https://www.alkermes.com